The estimated Net Worth of Steven Keith Burke is at least $1.93 Milhão dollars as of 29 February 2024. Dr Burke owns over 7,169 units of Akebia Therapeutics stock worth over $1,002,010 and over the last 10 years he sold AKBA stock worth over $247,744. In addition, he makes $681,869 as Sr. VP of R&D and Chief Medical Officer at Akebia Therapeutics.
Dr has made over 15 trades of the Akebia Therapeutics stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 7,169 units of AKBA stock worth $11,327 on 29 February 2024.
The largest trade he's ever made was exercising 70,221 units of Akebia Therapeutics stock on 10 March 2017 worth over $102,523. On average, Dr trades about 8,447 units every 75 days since 2015. As of 29 February 2024 he still owns at least 695,840 units of Akebia Therapeutics stock.
You can see the complete history of Dr Burke stock trades at the bottom of the page.
Dr. Steven Keith Burke is the Sr. VP of R&D and Chief Medical Officer at Akebia Therapeutics.
As the Sr. VP of R&D and Chief Medical Officer of Akebia Therapeutics, the total compensation of Dr Burke at Akebia Therapeutics is $681,869. There are 5 executives at Akebia Therapeutics getting paid more, with John Butler having the highest compensation of $4,316,960.
Dr Burke is 60, he's been the Sr. VP of R&D and Chief Medical Officer of Akebia Therapeutics since . There are 3 older and 15 younger executives at Akebia Therapeutics. The oldest executive at Akebia Therapeutics Inc. is Adrian Adams, 69, who is the Independent Chairman of the Board.
Steven's mailing address filed with the SEC is C/O AKEBIA THERAPEUTICS, INC, 245 FIRST STREET, CAMBRIDGE, MA, 02142.
Over the last 11 years, insiders at Akebia Therapeutics have traded over $3,056,393 worth of Akebia Therapeutics stock and bought 2,141,907 units worth $27,915,834 . The most active insiders traders include Holdings A/S Novo, Muneer A Satter, eMark J Enyedy. On average, Akebia Therapeutics executives and independent directors trade stock every 28 days with the average trade being worth of $43,534. The most recent stock trade was executed by Nicole R. Hadas on 13 May 2024, trading 12,016 units of AKBA stock currently worth $15,140.
akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.
Akebia Therapeutics executives and other stock owners filed with the SEC include: